A survey on tyrosine kinase inhibitor treatment in patients with chronic myeloid leukemia in China: from patients' perspective
10.3760/cma.j.issn.0253-2727.2016.07.004
- VernacularTitle:中国慢性髓性白血病患者酪氨酸激酶抑制剂治疗现状的调研:从患者的角度
- Author:
Qian JIANG
1
;
Zhengchen LIU
;
Songxin ZHANG
Author Information
1. 100044,北京大学人民医院、北京大学血液病研究所、造血干细胞移植治疗血液病北京市重点实验室
- Keywords:
Leukemia,myeloid,chronic,BCR-ABL (+);
Tyrosine kinase inhibitor;
Treatment outcome;
Questionnaires
- From:
Chinese Journal of Hematology
2016;37(7):559-564
- CountryChina
- Language:Chinese
-
Abstract:
Objectives To assess tyrosine kinase inhibitor (TKI) treatment status in patients with chronic myeloid leukemia (CML) in China and analyze the response-associated factors.Methods From May to November in 2014,anonymous questionnaires were distributed to adult CML patients who were receiving TKI treatment all over China.Results 1 038 questionnaires were collected,949 questionnaires were evaluable.Of the 949 evaluable respondents,549 (58％) were male with the median age of 41 years (range,18 to 88 years).623 (66％) respondents lived in an urban area and 449 (47％) had an education level ≥ a bachelor degree.888 (94％) respondents were in the chronic phase at diagnosis,and 690 (78％) of them started TKI treatment within one year after diagnosis.794 (84％) respondents were on imatinib,768 (81％) on the branded.With a median TKI treatment duration of 3 years (range,＜1 to 13 years),708 of 834 (85％) evaluable respondents achieved Ph-negative (i.e.complete cytogenetic response,CCyR),and 497 of 859 (46％) BCR-ABL negative (i.e.complete molecular response,CMR).Multivariate analyses showed that female (OR=l.8,95％ CI 1.1-2.8,P=0.019 and OR=l.5,95％CI 1.1-2.0,P=0.015),TKI treatment duration ＞3 years (OR=4.1,95％CI 2.6-6.5,P＜0.001 and OR=3.7,95％CI 2.7-5.1,P＜ 0.001) and imatinib taken (OR=2.1,95％CI 1.2-3.7,P=0.007 and OR=3.3,95％CI 2.1-5.1,P＜0.001) were factors affecting achieving both CCyR and CMR.In addition,higher education level (OR=2.0,95％CI 1.3-3.1,P=0.003),starting TKI treatment ＜1 year (OR=2.4,95％CI 1.5-3.8,P＜0.001) and branded drugs received (OR=2.4,95％ CI 1.4-4.0,P=0.001) were factors affecting achieving a CCyR.In 884 respondents,534 (62％) reported "heavy financial burden" as the biggest treatment impediment,only 152 (17％) reported "poor quality of life related to adverse effects of TKI".Conclusions The survey showed that majority of the Chinese CML patients received imatinib as a TKI therapy,and most of the patients achieved satisfied responses by TKI.Financial burden became the major obstacle during TKI treatment.
